Evidence map›Paper›PMID 30096313›Full record

ArticleCell2018

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.

Erica Ollmann Saphire, Sharon L Schendel, Marnie L Fusco, Karthik Gangavarapu, Bronwyn M Gunn, Anna Z Wec, Peter J Halfmann, Jennifer M Brannan, Andrew S Herbert, Xiangguo Qiu and 39 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

159 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

99 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

49 authors.

Erica Ollmann SaphireDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: erica@scripps.edu.
Sharon L SchendelDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Marnie L FuscoDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Karthik GangavarapuDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Bronwyn M GunnRagon Institute, Cambridge, MA 02139, USA.
Anna Z WecDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Peter J HalfmannDivision of Pathobiological Sciences, University of Wisconsin, Madison, WI 53706, USA.
Jennifer M BrannanDivision of Virology, United States Army Research Institute for Infectious Diseases, Ft. Detrick, MD 21702, USA.
Andrew S HerbertDivision of Virology, United States Army Research Institute for Infectious Diseases, Ft. Detrick, MD 21702, USA.
Xiangguo QiuNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg R3E 3R2, Canada.
Kshitij WaghLos Alamos National Laboratory, Los Alamos, NM 87545, USA.
Shihua HeNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg R3E 3R2, Canada.
Elena E GiorgiLos Alamos National Laboratory, Los Alamos, NM 87545, USA.
James TheilerLos Alamos National Laboratory, Los Alamos, NM 87545, USA.
Kathleen B J PommertDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Tyler B KrauseDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Hannah L TurnerIntegrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Charles D MurinIntegrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Jesper PallesenIntegrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Edgar DavidsonIntegral Molecular, Philadelphia, PA 19104, USA.
Rafi AhmedEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.
M Javad AmanIntegrated BioTherapeutics, Rockville, MD 20850, USA.
Alexander BukreyevGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA.
Dennis R BurtonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
James E CroweVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Carl W DavisEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.
George GeorgiouDepartment of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Christos A KyratsousRegeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.
Jonathan R LaiBiochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Cory NykiforukEmergent BioSolutions, Winnipeg, Manitoba, R3T 5Y3, Canada.
Michael H PaulyMapp Biopharmaceutical, San Diego, CA 92121, USA.
Pramila RijalHuman Immunology Unit, University of Oxford, Oxford OX3 9DS, UK.
Ayato TakadaResearch Center for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan.
Alain R TownsendHuman Immunology Unit, University of Oxford, Oxford OX3 9DS, UK.
Viktor VolchkovINSERM CNRS, Université Lyon, Lyon, France.
Laura M WalkerAdimab, LLC. Lebanon, NH 03766, USA.
Cheng-I WangSingapore Immunology Network, Agency for Science, Technology and Research (A(∗)STAR), Biopolis 138648, Singapore.
Larry ZeitlinMapp Biopharmaceutical, San Diego, CA 92121, USA.
Benjamin J DoranzIntegral Molecular, Philadelphia, PA 19104, USA.
Andrew B WardIntegrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Bette KorberLos Alamos National Laboratory, Los Alamos, NM 87545, USA.
Gary P KobingerDépartement de Microbiologie-Infectiologie et d'Immunologie, Médecine, Université Laval Quebec, G1V 046 Canada. Electronic address: gary.kobinger@crchudequebec.ulaval.ca.
Kristian G AndersenDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: andersen@scripps.edu.
Yoshihiro KawaokaDivision of Pathobiological Sciences, University of Wisconsin, Madison, WI 53706, USA. Electronic address: kawaokay@svm.vetmed.wisc.edu.
Galit AlterRagon Institute, Cambridge, MA 02139, USA. Electronic address: galter@mgh.harvard.edu.
Kartik ChandranDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA. Electronic address: kartik.chandran@einstein.yu.edu.
John M DyeDivision of Virology, United States Army Research Institute for Infectious Diseases, Ft. Detrick, MD 21702, USA. Electronic address: john.m.dye1.civ@mail.mil.
Viral Hemorrhagic Fever Immunotherapeutic Consortium

Funding

Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Bryan Briney · 2018 to 2026
$32.0M
Mechanistic Virology CoreU19AI109762 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SAPHIRE, ERICA OLLMANN · 2014 to 2018
$29.6M
Host-virus interactions in the control of filovirus entryR01AI134824 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CHANDRAN, KARTIK · 2018 to 2021
$1.9M
NIAID NIH HHS R01 AI134824NIAID NIH HHS U19 AI109762NIAID NIH HHS U19 AI135995
6 · The paper itself

Abstract

Antibodies are promising post-exposure therapies against emerging viruses, but which antibody features and in vitro assays best forecast protection are unclear. Our international consortium systematically evaluated antibodies against Ebola virus (EBOV) using multidisciplinary assays. For each antibody, we evaluated epitopes recognized on the viral surface glycoprotein (GP) and secreted glycoprotein (sGP), readouts of multiple neutralization assays, fraction of virions left un-neutralized, glycan structures, phagocytic and natural killer cell functions elicited, and in vivo protection in a mouse challenge model. Neutralization and induction of multiple immune effector functions (IEFs) correlated most strongly with protection. Neutralization predominantly occurred via epitopes maintained on endosomally cleaved GP, whereas maximal IEF mapped to epitopes farthest from the viral membrane. Unexpectedly, sGP cross-reactivity did not significantly influence in vivo protection. This comprehensive dataset provides a rubric to evaluate novel antibodies and vaccine responses and a roadmap for therapeutic development for EBOV and related viruses.

Indexed as

AnimalsAntibodies, MonoclonalEbolavirusEpitopesFemaleHemorrhagic Fever, EbolaImmunizationMembrane GlycoproteinsMiceMice, Inbred BALB CTreatment OutcomeAntibodies, MonoclonalEpitopesMembrane Glycoproteinsantibodyconsortiumebola virusepitopeglycoproteinneutralizationprotection

Identifiers

PMID30096313
PMCPMC6102396

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.